Archive


Category: (opaganib)

  • New ways to treat COVID: the pharmaphorum podcast

    In episode 31 of the pharmaphorum podcast, Deep Dive editor George Underwood speaks to RedHill biopharma’s chief business officer Guy Goldberg about the potential for new COVID-19 therapeutics to help fight the pandemic and treat patients in the years to come. Prior to joining RedHill, Guy served as senior vice president of business operations at […]

  • RedHill Reports Results of Yeliva (opaganib) in P-II Study for COVID-19

    Shots: The P-II US study involves assessing Opaganib + SOC vs PBO + SOC in 40 patients requiring oxygen support in a ratio (1:1) and were followed up for ~42days post-treatment initiation The study demonstrated improvement in reaching room air within 14days (52.6% vs 22.2%); improvement in reduction to 50% supplemental oxygen by Day 14 […]